S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day

Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

$21.72
-0.60 (-2.69%)
(As of 04/12/2024 08:52 PM ET)
Today's Range
$21.52
$22.24
50-Day Range
$21.22
$24.57
52-Week Range
$11.22
$25.34
Volume
618,700 shs
Average Volume
1.16 million shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.42

Syndax Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
58.5% Upside
$34.42 Price Target
Short Interest
Bearish
11.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.48mentions of Syndax Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.70) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.22 out of 5 stars

Medical Sector

339th out of 928 stocks

Pharmaceutical Preparations Industry

146th out of 417 stocks

SNDX stock logo

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Stock Price History

SNDX Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
SNDX Apr 2024 17.500 put
See More Headlines
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/14/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNDX
Employees
184
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.42
High Stock Price Target
$45.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+58.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-209,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$139.71 million
Book Value
$6.53 per share

Miscellaneous

Free Float
80,972,000
Market Cap
$1.85 billion
Optionable
Optionable
Beta
1.03
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael A. Metzger M.B.A.Mr. Michael A. Metzger M.B.A. (Age 53)
    CEO & Director
    Comp: $1.1M
  • Dr. Peter Ordentlich B.Sc. (Age 55)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Dr. Richard A. Heyman Ph.D. (Age 67)
    Co-Founder
  • Dr. Ronald M. Evans Ph.D. (Age 75)
    Co-Founder, Advisor and Chair of Scientific Advisory Board
  • Dr. Michael Downes Ph.D.
    Co-Founder
  • Sharon Klahre
    Vice President of Investor Relations & Communications
  • Mr. Kevin McManus (Age 55)
    Chief People Officer
  • Dr. Joseph Paul Eder M.D.
    Member of Scientific Advisory Board & Chief Medical Officer
  • Dr. Anjali Ganguli Ph.D. (Age 47)
    Chief Business Officer
    Comp: $450.58k
  • Mr. Steven Closter
    Chief Commercial Officer

SNDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNDX shares.
View SNDX analyst ratings
or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price target for 2024?

10 Wall Street research analysts have issued 1 year price objectives for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $23.00 to $45.00. On average, they predict the company's share price to reach $34.42 in the next year. This suggests a possible upside of 58.5% from the stock's current price.
View analysts price targets for SNDX
or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2024?

Syndax Pharmaceuticals' stock was trading at $21.61 at the start of the year. Since then, SNDX stock has increased by 0.5% and is now trading at $21.72.
View the best growth stocks for 2024 here
.

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SNDX earnings forecast
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its earnings results on Tuesday, February, 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by $0.01. During the same period last year, the company posted ($0.62) earnings per share.

What ETFs hold Syndax Pharmaceuticals' stock?

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Range Cancer Therapeutics ETF (CNCR), Simplify Propel Opportunities ETF (SURI) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK).

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNDX) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners